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Abstract. Rapamycin, an inhibitor of mechanistic target of rapamy-
cin complex 1 (mTORC1), extends the life spans of yeast, ﬂies, and
mice. Calorie restriction, which increases life span and insulin sensi-
tivity, is proposed to function by inhibition of mTORC1, yet paradox-
ically, chronic administration of rapamycin substantially impairs
glucose tolerance and insulin action. We demonstrate that rapamy-
cin disrupted a second mTOR complex, mTORC2, in vivo and that
mTORC2 was required for the insulin-mediated suppression of hepa-
tic gluconeogenesis. Further, decreased mTORC1 signaling was sufﬁ-
cient to extend life span independently from changes in glucose
homeostasis, as female mice heterozygous for both mTOR and mLST8
exhibited decreased mTORC1 activity and extended life span but had
normal glucose tolerance and insulin sensitivity. Thus, mTORC2 dis-
ruption is an important mediator of the effects of rapamycin in vivo.
 2012 European Association for the Study of the Liver. Published
by Elsevier Inc. All rights reserved
Although many of us hope for a long life, this wish is undoubtedly
tied to the concept of healthy life. Thus, an anticipated thinking is
that health is a prerequisite for longevity. This corollary has been
recently challenged in a study published in Science, where Lam-
ming and colleagues report that rapamycin extends lifespan of
mice by inhibition of mTORC1, despite impairing glucose homeo-
stasis through the disruption of mTORC2 signaling [1]. The mam-
malian target of rapamycin (mTOR) is a protein kinase linked to
two distinct multi-protein complexes: mTORC1 and mTORC2.
Within these complexes, the proteins raptor and rictor are boundJournal of Hepatology 20
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E-mail address: sara.kozma@uc.edu (S.C. Kozma).to mTORC1 or mTORC2, respectively, while mLST8 is associated
with both mTORC1 and mTORC2. mTORC1 regulates pathways
involved in cell growth, metabolism and aging, while mTORC2
is involved in cytoskeleton and insulin signaling regulation [2].
Downstream of mTORC1, the ribosomal S6 protein kinase
(S6K1) has been identiﬁed as a key player for the role of mTORC1
[2]. Genetic attenuation of mTORC1 signaling was shown to
extend lifespan in yeast, nematodes, fruit ﬂies, as well as mice
[4]. Interestingly, knocking out S6K1 led to improved insulin sen-
sitivity [3] and induced gene expression patterns similar to those
seen in caloric restriction [4]. For several years, caloric restriction
has been known to increase lifespan in mammals [5]. Caloric
restriction reduced mTORC1 signaling but also improved glucose
tolerance as well as insulin sensitivity and these effects have
been shown to positively inﬂuence longevity [5]. Along the line
that implies the role of mTORC1 in longevity, the activity of the
mTORC1/S6K1 signaling pathway increases with aging, while
S6K1 deletion leads to increased lifespan and resistance to age-
related pathologies [4]. On the other hand, mTORC2 is largely
insensitive to rapamycin in an acute setting; however, it can be
inhibited by chronic exposure to rapamycin [6]. It was demon-
strated that chronic treatment with rapamycin caused glucose
intolerance in humans and rodents [7,8]. One therefore would
predict that the deleterious effects of chronic rapamycin treat-
ment on glucose homeostasis would hamper the life-extending
effects of mTORC1 inhibition. However, mice fed rapamycin late
in life had their median and maximal lifespan extended [9]. Hav-
ing this paradox in mind, Lamming and colleagues [10] veriﬁed
whether chronic rapamycin treatment, at a dose used to increase
lifespan, would induce glucose intolerance and increased
gluconeogenesis. They demonstrated in vivo that rapamycin not
only disrupted the mTORC1 complex in muscle, adipose and liver
tissues, but also affected mTORC2 assembling in the same tissues.
This was further conﬁrmed by ﬁnding reduced phosphory-
lation of the mTORC2 substrates PKCa-S657, AKT-S473, and
NDRG1-T346 in all tissues studied upon refeeding of mice or
insulin stimulation [1]. Using hyperinsulinemic-euglycemic
clamps, the authors showed that rapamycin speciﬁcally affected
the efﬁciency of insulin to suppress hepatic glucose production
[1]. By conditionally deleting either raptor or rictor in the mouse
liver, or by using livers from rictor knockout animals, the authors
established that disruption of mTORC2 signaling, but not
mTORC1, impaired glucose tolerance and induced hepatic gluco-
neogenesis by increased hepatic glucose production [1]. This12 vol. 57 j 1368–1369
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Fig. 1. The two sides of a dagger represent both effects of rapamycin treatment: on one side, inhibition of mTORC1 signaling increases lifespan and, on the other
side, inhibition of mTORC2 affects glucose homeostasis.
JOURNAL OF HEPATOLOGYeffect was not further affected by rapamycin treatment. However,
livers from raptor knockout mice had normal glucose homeosta-
sis and remained rapamycin sensitive. Together these observa-
tions suggested that chronic rapamycin treatment at a dose
used to extend lifespan, impaired hepatic glucose homeostasis
by induction of gluconeogenesis, an effect mediated by mTORC2
disruption. However, can the paradoxical effects of mTORC1 and
mTORC2 inhibition be dissociated? To test that, Lamming and
colleagues generated several mice carrying only one allele of dif-
ferent components of the mTORC1 (Mtor+/, Raptor+/, Mlst8+/)
or double-mutants (Mtor+/Raptor+/ and Mtor+/Mlst8+/ mice).
Similar to what described for S6K1 deletion [4], the female
Mtor+/Mlst8+/ mice showed an increased lifespan and this was
accompanied by normal glucose tolerance. Interestingly,
although both mTOR and mlst8 are present in both complexes,
hepatic mTORC1 signalling was reduced in Mtor+/Mlst8+/
female mice, whereas mTORC2 signalling was not affected. This
corresponded to a lower raptor–mTOR ratio compared to ric-
tor–mTOR ratio, bringing the authors to hypothesize a recruit-
ment of mTOR and mlst8 to mTORC2 when protein amounts
were limited. The data from Lamming and colleagues strongly
suggest that selective inhibition of mTORC1 or mTORC2 signaling
results in lifespan extension and glucose homeostasis impair-
ment, respectively (Fig. 1). However, it is unclear whether rapa-
mycin treatment extends lifespan by postponing death from
age-related pathologies and/or by retarding other cellular mech-
anisms of aging. For instance, while Harrison et al. [9] showed
that mice fed rapamycin live longer, they did not report on the
mouse glucose-homeostasis status, their body weight or food
intake. However, more recent studies have shown that feeding
or intraperitonealy injections of rapamycin reduce body weight
and food intake of rodents [6]. Conversely, while Lamming et al.
reported a clear effect of rapamycin treatment on glucose homeo-
stasis, the changes in body weight and lifespan under the rapa-
mycin-induced insulin resistance were not determined. Indeed,
female Mtor+/Mlst8+/ mice, which lived longer, had apparently
normal glucose tolerance. All these data together suggest that
the ability of mTORC1 inhibition to extend lifespan may involve
maintenance of glucose homeostasis. Accordingly, it has been
shown that fat-speciﬁc insulin receptor knockout mice have
reduced fat mass without caloric restriction, which is associatedJournal of Hepatology 2012with increased longevity; possibly through improvement of insu-
lin signaling in the remaining body tissues [10]. The determina-
tion of whether the effects of rapamycin treatment on longevity
require changes in body weight and composition, food intake,
and glucose homeostasis would help gain insight into the mech-
anism by which mTOR complexes inﬂuence lifespan.Conﬂict of interest
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